Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 607246, 7 pages
http://dx.doi.org/10.1155/2014/607246
Research Article

Olmesartan Attenuates Tacrolimus-Induced Biochemical and Ultrastructural Changes in Rat Kidney Tissue

1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
2Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
3El-Ghad International College for Health Science, Riyadh 11451, Saudi Arabia
4Al-Haya Medical Co., Riyadh 11411, Saudi Arabia

Received 20 March 2014; Accepted 10 May 2014; Published 28 May 2014

Academic Editor: Raul Lombardi

Copyright © 2014 Naif O. Al-Harbi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-U. Meier-Kriesche, S. Li, R. W. G. Gruessner et al., “Immunosuppression: evolution in practice and trends, 1994–2004,” The American Journal of Transplantation, vol. 6, no. 5, pp. 1111–1131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Haynes, C. Baigent, P. Harden et al., “Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol,” Transplantation Research, vol. 2, pp. 1–9, 2013. View at Publisher · View at Google Scholar
  3. E. H. Bae, I. J. Kim, S. Y. Joo et al., “Renoprotective effects of the direct renin inhibitor aliskiren on gentamicin-induced nephrotoxicity in rats,” Journal of Renin Angiotensin Aldosterone System, 2013. View at Publisher · View at Google Scholar
  4. X. Zhou, G. Yang, C. A. Davis et al., “Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells,” Kidney International, vol. 65, no. 1, pp. 139–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. H. Gradman, R. E. Schmieder, R. L. Lins, J. Nussberger, Y. Chiang, and M. P. Bedigian, “Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients,” Circulation, vol. 111, no. 8, pp. 1012–1018, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Morales, L. Wramner, H. Kreis et al., “Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients,” The American Journal of Transplantation, vol. 2, no. 5, pp. 436–442, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. K. Khanna and G. M. Pieper, “NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model,” Nephrology Dialysis Transplantation, vol. 22, no. 2, pp. 376–385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Kurtz, R. Della Bruna, and K. Kuhn, “Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells,” Kidney International, vol. 33, no. 5, pp. 947–953, 1988. View at Google Scholar · View at Scopus
  9. K. Höcherl, F. Dreher, H. Vitzthum, J. Köhler, and A. Kurtz, “Cyclosporine a suppresses cyclooxygenase-2 expression in the rat kidney,” Journal of the American Society of Nephrology, vol. 13, no. 10, pp. 2427–2436, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. L. G. Cook, V. L. Chiasson, C. Long, G.-Y. Wu, and B. M. Mitchell, “Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect,” Kidney International, vol. 75, no. 7, pp. 719–726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Anderson, F. F. Jung, and J. R. Ingelfinger, “Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations,” The American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 265, no. 4, pp. F477–F486, 1993. View at Google Scholar · View at Scopus
  12. S. Anderson, H. G. Rennke, and B. M. Brenner, “Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat,” Journal of Clinical Investigation, vol. 77, no. 6, pp. 1993–2000, 1986. View at Google Scholar · View at Scopus
  13. S. Kagami, W. A. Border, D. E. Miller, and N. A. Noble, “Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells,” Journal of Clinical Investigation, vol. 93, no. 6, pp. 2431–2437, 1994. View at Google Scholar · View at Scopus
  14. P. Ruggenenti, A. Perna, G. Gherardi et al., “Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria,” The Lancet, vol. 354, no. 9176, pp. 359–364, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. M. D. Flather, S. Yusuf, L. Køber et al., “Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.,” The Lancet, vol. 355, no. 9215, pp. 1575–1581, 2000. View at Google Scholar · View at Scopus
  16. A.-C. Huby, M.-P. Rastaldi, K. Caron, O. Smithies, J.-C. Dussaule, and C. Chatziantoniou, “Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin,” PLoS ONE, vol. 4, no. 8, Article ID e6721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. E. Pueyo, W. Gonzalez, A. Nicoletti, F. Savoie, J.-F. Arnal, and J.-B. Michel, “Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 645–651, 2000. View at Google Scholar · View at Scopus
  18. M. Ushio-Fukai, K. K. Griendling, P. L. Becker, L. Hilenski, S. Halleran, and R. W. Alexander, “Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 489–495, 2001. View at Google Scholar · View at Scopus
  19. G. Viberti and N. M. Wheeldon, “Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect,” Circulation, vol. 106, no. 6, pp. 672–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Mitamura, A. Yamada, H. Ishida et al., “Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats,” Journal of Toxicological Sciences, vol. 19, no. 4, pp. 219–226, 1994. View at Google Scholar · View at Scopus
  21. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at Google Scholar · View at Scopus
  22. O. H. Lowry, N. J. Rosenburg, A. Farr et al., “Protein measurement with the Folin phenol reagent,” The Journal of biological chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  23. J. Sedlak and R. H. Lindsay, “Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent,” Analytical Biochemistry, vol. 25, pp. 192–205, 1968. View at Google Scholar · View at Scopus
  24. A. Clairborne, “Catalase activity,” in Handbook of Methods for Oxygen Radical Research, R. A. Greenwald, Ed., pp. 283–284, CRC Press, Boca Raton, Fla, USA, 1985. View at Google Scholar
  25. J. Tong, P. K. Ganguly, and P. K. Singal, “Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 260, no. 3, pp. H909–H916, 1991. View at Google Scholar · View at Scopus
  26. E. S. Reyenolds, “The use of lead citrate at high pH as an electron-opaque stain in electron microscopy,” The Journal of Cell Biology, vol. 17, pp. 208–212, 1963. View at Google Scholar · View at Scopus
  27. S. A. Mifsud, T. J. Allen, J. F. Bertram et al., “Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade,” Diabetologia, vol. 44, no. 7, pp. 878–882, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Whaley-Connell, R. Nistala, J. Habibi et al., “Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat,” The American Journal of Physiology—Renal Physiology, vol. 298, no. 3, pp. F655–F661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. A. Fouad and I. Jresat, “Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice,” Life Sciences, vol. 89, no. 1-2, pp. 29–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Haghighi, M. Nematbakhsh, A. Talebi et al., “The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences,” Renal Failure, vol. 34, no. 8, pp. 1046–1051, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Wood, J. Maibaum, J. Rahuel et al., “Structure-based design of aliskiren, a novel orally effective renin inhibitor,” Biochemical and Biophysical Research Communications, vol. 308, no. 4, pp. 698–705, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. P. S. Randhawa, T. E. Starzl, and A. J. Demetris, “Tacrolimus (FK506)-associated renal pathology,” Advance Anatomy and Pathology, vol. 4, pp. 265–276, 1997. View at Google Scholar
  33. S. Yilmaz, A. Atessahin, E. Sahna, I. Karahan, and S. Ozer, “Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity,” Toxicology, vol. 218, no. 2-3, pp. 164–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. Ibrahim, O. M. Ashour, Y. F. Ibrahim, H. I. EL-Bitar, W. Gomaa, and S. R. Abdel-Rahim, “Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity,” Pharmacological Research, vol. 60, no. 5, pp. 373–381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. N. A. El-Shitany, S. El-Haggar, and K. El-desoky, “Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats,” Food and Chemical Toxicology, vol. 46, no. 7, pp. 2422–2428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Rashikh, K. K. Pillai, S. J. Ahmad, M. Akhtar, and A. K. Najmi, “Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 14, no. 1, pp. 14–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Okuda, Y. Oh, H. Tsuruda, K. Onoyama, S. Fujimi, and M. Fujishima, “Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease,” Kidney International, vol. 29, no. 2, pp. 502–510, 1986. View at Google Scholar · View at Scopus
  38. M. P. O'Donnell, L. Michels, B. Kasiske, L. Raij, and W. F. Keane, “Adriamycin-induced chronic proteinuria: a structural and functional study,” Journal of Laboratory and Clinical Medicine, vol. 106, no. 1, pp. 62–67, 1985. View at Google Scholar · View at Scopus
  39. M. A. Mansour, H. A. El-Kashef, and O. A. Al-Shabanah, “Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats,” Pharmacological Research, vol. 39, no. 3, pp. 233–237, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Venkatesan, D. Punithavathi, and V. Arumugam, “Curcumin prevents adriamycin nephrotoxicity in rats,” British Journal of Pharmacology, vol. 129, no. 2, pp. 231–234, 2000. View at Google Scholar · View at Scopus
  41. C. E. Myers, W. P. McGuire, R. H. Liss, I. Ifrim, K. Grotzinger, and R. C. Young, “Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response,” Science, vol. 197, no. 4299, pp. 165–167, 1977. View at Google Scholar · View at Scopus
  42. D. Kumar, L. A. Kirshenbaum, T. Li, I. Danelisen, and P. K. Singal, “Apoptosis in adriamycin cardiomyopathy and its modulation by probucol,” Antioxidants and Redox Signaling, vol. 3, no. 1, pp. 135–145, 2001. View at Google Scholar · View at Scopus
  43. K. C. Lee, C. C. Chan, Y. Y. Yang et al., “Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet,” PLoS ONE, vol. 8, no. 10, Article ID e77817, 2013. View at Google Scholar
  44. I. E. Stillman, T. F. Andoh, E. A. Burdmann, W. M. Bennett, and S. Rosen, “FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model,” Laboratory Investigation, vol. 73, no. 6, pp. 794–803, 1995. View at Google Scholar · View at Scopus
  45. H. Pavenstädt, W. Kriz, and M. Kretzler, “Cell biology of the glomerular podocyte,” Physiological Reviews, vol. 83, no. 1, pp. 253–307, 2003. View at Google Scholar · View at Scopus
  46. H. J. Jeong, Y. S. Kim, and I. C. Hong, “Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats,” Transplantation Proceedings, vol. 30, no. 7, pp. 3596–3597, 1998. View at Google Scholar · View at Scopus